StreetInsider.com News Articles

Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 5c

Thu, 06 Aug 2026 08:22:51 -0400

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of $0.28, $0.05 better than the analyst estimate of $0.23. Revenue for the quarter came in at $83.2 million versus the consensus estimate of $80.56 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

Form 10-Q Aurinia Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26879539.html

Form 10-Q Aurinia Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 08:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26879539.html

Form 8-K Aurinia Pharmaceuticals For: Aug 06

Thu, 06 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26879323.html

Form 8-K Aurinia Pharmaceuticals For: Aug 06

Thu, 06 Aug 2026 08:03:00 -0400

si-local-file:///var/storage/secattach/20260806/26879323.html

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Thu, 06 Aug 2026 08:00:00 -0400

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress.

Financial Results

Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025.
- Net Product Sales: For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Thu, 06 Aug 2026 08:00:00 -0400

Financial Results

Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025.
- Net Product Sales: For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Thu, 06 Aug 2026 08:00:00 -0400

Financial Results

Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025.
- Net Product Sales: For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Thu, 06 Aug 2026 08:00:00 -0400

Financial Results

Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025.
- Net Product Sales: For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the

Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs

Mon, 06 Jul 2026 08:03:02 -0400

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the initiation of PRESERVE, a Phase 4 multicenter study examining the combination of its drug Lupkynis with belimumab, obinutuzumab, or anifrolumab in patients with lupus nephritis, according to a company press release.

The study plans to enroll approximately 150 patients across roughly 50 sites in the United States. The primary endpoint is the proportion of patients achieving complete renal response at six months.

Lupkynis is FDA-approved as an oral therapy for lupus nephritis. Belimumab is approved for both systemic lupus erythematosus and lupus nephritis, obinutuzumab is approved for lupus nephritis, and anifrolumab is approved for systemic lupus

Aurinia starts Phase 4 study combining Lupkynis with other lupus drugs

Mon, 06 Jul 2026 08:03:02 -0400

The study plans to enroll approximately 150 patients across roughly 50 sites in the United States. The primary endpoint is the proportion of patients achieving complete renal response at six months.

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Mon, 06 Jul 2026 08:00:00 -0400